These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35792023)

  • 1. Assessment of thyroiditis risk associated with HPV vaccination among girls aged 9-18 years: A time-varying cohort study.
    Castillo-Cano B; Martín-Pérez M; Llorente-García A; Montero-Corominas D; Comas-Cufí M; Martín-Merino E
    Vaccine; 2022 Aug; 40(33):4816-4826. PubMed ID: 35792023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Risk of Inflammatory Bowel Disease after the HPV Vaccination in Primary Care in Spain: A Time-Varying Cohort Analysis of Around 390,000 Girls.
    Martín-Merino E; Castillo-Cano B; Martín-Pérez M; Llorente-García A; Montero-Corominas D
    Drug Saf; 2021 Apr; 44(4):455-466. PubMed ID: 33462777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
    Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
    Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
    Martín-Merino E; Castillo-Cano B; Martín-Perez M; Llorente-García A; Montero-Corominas D
    Vaccine; 2021 Jul; 39(31):4306-4313. PubMed ID: 34175126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recording of human papillomavirus (HPV) vaccination in BIFAP primary care database: A validation study.
    Martín-Merino E; Llorente-García A; Montero-Corominas D; Huerta C
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):201-208. PubMed ID: 30488510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.
    Yoon D; Lee JH; Lee H; Shin JY
    BMJ; 2021 Jan; 372():m4931. PubMed ID: 33514507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
    Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
    Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus vaccines and Guillain-Barré syndrome: managing uncertainties.
    Prescrire Int; 2016 Nov; 25(176):265-268. PubMed ID: 30715823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
    Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
    Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine.
    Rosillon D; Willame C; Tavares Da Silva F; Guignard A; Caterina S; Welby S; Struyf F
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1159-1167. PubMed ID: 32583515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.
    Liu EY; Smith LM; Ellis AK; Whitaker H; Law B; Kwong JC; Farrington P; Lévesque LE
    CMAJ; 2018 May; 190(21):E648-E655. PubMed ID: 29807937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA; Campos NG; Sy S; Regan C; Kim JJ
    Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.